2020
Androgenicity and fertility treatment in women with unexplained infertility
Wang ET, Diamond MP, Alvero R, Casson P, Christman GM, Coutifaris C, Hansen KR, Sun F, Legro RS, Robinson RD, Usadi RS, Pisarska MD, Santoro NF, Zhang H, Network I. Androgenicity and fertility treatment in women with unexplained infertility. Fertility And Sterility 2020, 113: 636-641. PMID: 32192596, PMCID: PMC7088440, DOI: 10.1016/j.fertnstert.2019.10.034.Peer-Reviewed Original ResearchConceptsLive birth rateBody mass indexUnexplained infertilityClinical pregnancyMass indexPregnancy lossClinical markersLive birthsAndrogenic activityFree androgen index valuesHigher body mass indexMultivariable logistic regression modelMultiple Intrauterine GestationsNormal uterine cavityHigh waist circumferenceOvarian stimulation treatmentPatent fallopian tubesBirth rateLogistic regression modelsAndrogen markersSerum TTOvarian stimulationRegular mensesInfertility populationIntrauterine gestation
2015
Letrozole, Gonadotropin, or Clomiphene for Unexplained Infertility
Diamond M, Legro R, Coutifaris C, Alvero R, Robinson R, Casson P, Christman G, Ager J, Huang H, Hansen K, Baker V, Usadi R, Seungdamrong A, Bates G, Rosen R, Haisenleder D, Krawetz S, Barnhart K, Trussell J, Ohl D, Jin Y, Santoro N, Eisenberg E, Zhang H. Letrozole, Gonadotropin, or Clomiphene for Unexplained Infertility. Obstetrical & Gynecological Survey 2015, 70: 757-758. DOI: 10.1097/ogx.0000000000000275.Peer-Reviewed Original ResearchOvarian stimulationUnexplained infertilityMultiple gestationsLetrozole groupCongenital anomaliesPregnancy rateLive birthsNormal uterine cavityStandard therapy groupUse of clomipheneOvarian hyperstimulation syndromeFirst-line therapyLive birth ratePatent fallopian tubesPolycystic ovary syndromeMultiple gestation ratesCause of infertilityPlacebo control groupNormal sperm countYears of ageImproved pregnancy ratesFetal heart activityHyperstimulation syndromeMonofollicular developmentNeonatal complicationsChlamydia trachomatis immunoglobulin G3 seropositivity is a predictor of reproductive outcomes in infertile women with patent fallopian tubes
Steiner AZ, Diamond MP, Legro RS, Schlaff WD, Barnhart KT, Casson PR, Christman GM, Alvero R, Hansen KR, Geisler WM, Thomas T, Santoro N, Zhang H, Eisenberg E, Network R. Chlamydia trachomatis immunoglobulin G3 seropositivity is a predictor of reproductive outcomes in infertile women with patent fallopian tubes. Fertility And Sterility 2015, 104: 1522-1526. PMID: 26413816, PMCID: PMC4663111, DOI: 10.1016/j.fertnstert.2015.08.022.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAntibodies, BacterialBiomarkersChi-Square DistributionChlamydia InfectionsChlamydia trachomatisEnzyme-Linked Immunosorbent AssayFallopian TubesFemaleHumansImmunoglobulin GInfertility, FemaleLinear ModelsLive BirthMultivariate AnalysisOdds RatioPredictive Value of TestsPregnancyPregnancy RatePregnancy, EctopicReproductive Techniques, AssistedRisk AssessmentRisk FactorsSerologic TestsTreatment OutcomeUltrasonographyYoung AdultConceptsEctopic pregnancySeropositive womenInfertile womenTubal patencyLive birthsPolycystic Ovary Syndrome IIChlamydia trachomatis seropositivityMultiple Intrauterine GestationsPatent fallopian tubesEnzyme-linked immunosorbentCurrent alcohol useC. trachomatis elementary bodiesOvarian stimulationCohort studyIntrauterine gestationPregnancy outcomesPrimary outcomeTreatment medicationsPatent tubesSmoking statusOutpatient clinicIgG3 antibodiesFallopian tubeRelative riskMAIN OUTCOMELetrozole, Gonadotropin, or Clomiphene for Unexplained Infertility
Diamond MP, Legro RS, Coutifaris C, Alvero R, Robinson RD, Casson P, Christman GM, Ager J, Huang H, Hansen KR, Baker V, Usadi R, Seungdamrong A, Bates GW, Rosen RM, Haisenleder D, Krawetz SA, Barnhart K, Trussell JC, Ohl D, Jin Y, Santoro N, Eisenberg E, Zhang H. Letrozole, Gonadotropin, or Clomiphene for Unexplained Infertility. New England Journal Of Medicine 2015, 373: 1230-1240. PMID: 26398071, PMCID: PMC4739644, DOI: 10.1056/nejmoa1414827.Peer-Reviewed Original ResearchConceptsUnexplained infertilityMultiple gestationsOvarian stimulationClinical pregnancyStandard therapyLive birth ratePatent fallopian tubesMultiple gestation ratesYears of ageFetal heart activityLetrozole groupNeonatal complicationsClomiphene citrateTriplet gestationsOngoing pregnancyPrimary outcomeGonadotropin treatmentFallopian tubeGestation rateCongenital anomaliesPregnancy rateWomen 18Live birthsClomipheneLetrozole
2014
Letrozole Versus Clomiphene for Infertility in the Polycystic Ovary Syndrome
Legro R, Brzyski R, Diamond M, Coutifaris C, Schlaff W, Casson P, Christman G, Huang H, Yan Q, Alvero R, Haisenleder D, Barnhart K, Bates G, Usadi R, Lucidi S, Baker V, Trussell J, Krawetz S, Snyder P, Ohl D, Santoro N, Eisenberg E, Zhang H. Letrozole Versus Clomiphene for Infertility in the Polycystic Ovary Syndrome. Obstetrical & Gynecological Survey 2014, 69: 599-601. DOI: 10.1097/01.ogx.0000456355.64379.77.Peer-Reviewed Original ResearchPolycystic ovary syndromeAdverse effect profileMultiple pregnancy rateEffect profileFertility agentsAromatase inhibitorsLive birthsHigher multiple pregnancy rateLower multiple pregnancy rateSelective estrogen receptor modulatorsMale partnersNormal uterine cavityPatent fallopian tubesPrimary study outcomeCumulative live birthReproductive-age womenGood safety profileEstrogen receptor modulatorsClomiphene groupLetrozole groupClomiphene citrateRotterdam criteriaHot flushesOvary syndromeInfertile womenLetrozole versus Clomiphene for Infertility in the Polycystic Ovary Syndrome
Legro RS, Brzyski RG, Diamond MP, Coutifaris C, Schlaff WD, Casson P, Christman GM, Huang H, Yan Q, Alvero R, Haisenleder DJ, Barnhart KT, Bates GW, Usadi R, Lucidi S, Baker V, Trussell JC, Krawetz SA, Snyder P, Ohl D, Santoro N, Eisenberg E, Zhang H. Letrozole versus Clomiphene for Infertility in the Polycystic Ovary Syndrome. New England Journal Of Medicine 2014, 371: 119-129. PMID: 25006718, PMCID: PMC4175743, DOI: 10.1056/nejmoa1313517.Peer-Reviewed Original ResearchConceptsPolycystic ovary syndromeOvary syndromeCongenital anomaliesLive birthsHigh incidenceOvulation rateSignificant between-group differencesCumulative ovulation rateNormal uterine cavityOverall congenital anomaliesBetter pregnancy outcomesPatent fallopian tubesCumulative live birthMajor congenital anomaliesBetween-group differencesYears of ageClomiphene groupLetrozole groupRotterdam criteriaAdverse eventsHot flushesPregnancy outcomesInfertile womenMulticenter trialPrimary outcome